Literature DB >> 18574709

Osteoporosis after combined use of a neuroleptic and antidepressants.

Gert Laekeman1, Lieven Zwaenepoel, Johan Reyntens, Marc de Vos, Minne Casteels.   

Abstract

UNLABELLED: Bone mineral density may be negatively influenced by hyperprolactinemia, which can be caused by atypic neuroleptics and antidepressants. CASE DESCRIPTION: The present paper reports about a spontaneous rib fracture in a female patient (age 52) taking neuroleptics (mainly risperidone), antidepressants (mainly sertraline), and anxiolytics (mainly lorazepam). At the time of the fracture a severe osteoporosis and a strongly enhanced plasma prolactin level (117 ng/ml; normal values: 3-24 ng/ml) were detected. The latter one normalized 2 months after abandoning sertraline and risperidone. After this normalization, the patient did not report further accidents up to now. DISCUSSION: Enhancement of plasma prolactin levels is linked to the mechanism of action of risperidone. Mammoplasia and increased plasma prolactin can occur during SSRI (Selective Serotonin Reuptake Inhibitors) or trazodone administration. The role of anxiolytics is less clear. The causal relationship between osteoporosis and long-term use of neuroleptics and antidepressants was assessed using probability scores, more particularly the Naranjo probability scale and the Bradford-Hill criteria of causality. A score of 6/13 (probable) was obtained with the Naranjo scale, whereas all 9 Bradford-Hill criteria were fulfilled.
CONCLUSION: Although this case could not be fully explored, attention should be paid to bone mineral density loss in depressed patients taking a combined therapy of atypic antipsychotics and antidepressants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574709     DOI: 10.1007/s11096-008-9231-6

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  15 in total

1.  Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.

Authors:  Saad A W Shakir; Deborah Layton
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

Authors:  M G Scordo; E Spina; G Facciolà; A Avenoso; I Johansson; M L Dahl
Journal:  Psychopharmacology (Berl)       Date:  1999-12       Impact factor: 4.530

Review 3.  Pharmacology and clinical experience with risperidone.

Authors:  R C Love; M W Nelson
Journal:  Expert Opin Pharmacother       Date:  2000-12       Impact factor: 3.889

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.

Authors:  Miloslav Kopecek; Martin Bares; Jirí Horacek; Pavel Mohr
Journal:  Neuro Endocrinol Lett       Date:  2006-12       Impact factor: 0.765

6.  Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

Authors:  Lei Wang; Lan Yu; Ai-Ping Zhang; Chao Fang; Jing Du; Niu-Fan Gu; Sheng-Ying Qin; Guo-Yin Feng; Xing-Wang Li; Qing-He Xing; Lin He
Journal:  J Psychopharmacol       Date:  2007-08-22       Impact factor: 4.153

7.  Effects of the short-acting benzodiazepine triazolam, taken at bedtime, on circadian and sleep-related hormonal profiles in normal men.

Authors:  G Copinschi; A Van Onderbergen; M L'Hermite-Balériaux; M Szyper; A Caufriez; D Bosson; M L'Hermite; C Robyn; F W Turek; E Van Cauter
Journal:  Sleep       Date:  1990-06       Impact factor: 5.849

8.  [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].

Authors:  Mirijam Fric; Gerd Laux
Journal:  Psychiatr Prax       Date:  2003-05

9.  Low bone mass in premenopausal women with depression.

Authors:  Farideh Eskandari; Pedro E Martinez; Sara Torvik; Terry M Phillips; Esther M Sternberg; Sejal Mistry; Donna Ronsaville; Robert Wesley; Caitlin Toomey; Nancy G Sebring; James C Reynolds; Marc R Blackman; Karim A Calis; Philip W Gold; Giovanni Cizza
Journal:  Arch Intern Med       Date:  2007-11-26

10.  Trazodone treatment increases plasma prolactin concentrations in depressed patients.

Authors:  K Otani; N Yasui; S Kaneko; M Ishida; T Ohkubo; T Osanai; K Sugawara; Y Fukushima
Journal:  Int Clin Psychopharmacol       Date:  1995-06       Impact factor: 1.659

View more
  6 in total

1.  [Validation of interaction databases in psychopharmacotherapy].

Authors:  M Hahn; S C Roll
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

Review 2.  Towards a serotonin-dependent leptin roadmap in the brain.

Authors:  Franck Oury; Gerard Karsenty
Journal:  Trends Endocrinol Metab       Date:  2011-05-24       Impact factor: 12.015

3.  Connections between the outcomes of osteoporotic hip fractures and depression, delirium or dementia in elderly patients: rationale and preliminary data from the CODE study.

Authors:  Prisco Piscitelli; Alessia Metozzi; Enrico Benvenuti; Lorenzo Bonamassa; Gemma Brandi; Loredana Cavalli; Emanuela Colli; Caterina Fossi; Simone Parri; Lorenzo Giolli; Annalisa Tanini; Alfonso Fasano; Gianluca Di Tanna; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

4.  Involvement of the TNF-α/SATB2 axis in the induced apoptosis and inhibited autophagy of osteoblasts by the antipsychotic Risperidone.

Authors:  Shuyao Zhang; Wei He; Aiguo Li; Chengkuan Zhao; Yun Chen; Chengcheng Xu; Qiuzhen Zhang; Danling Zheng; Meini Chen; Haixiong Miao; Yihui Huang
Journal:  Mol Med       Date:  2022-05-03       Impact factor: 6.376

Review 5.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 6.  Biology without walls: the novel endocrinology of bone.

Authors:  Gerard Karsenty; Franck Oury
Journal:  Annu Rev Physiol       Date:  2011-11-07       Impact factor: 22.163

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.